All reports.

National Resilience, Inc. (Resilience)

Research-more: Resilience has real strategic manufacturing value and unusually strong Lilly-backed validation for a private CDMO, but the post-2025 reset, leverage, and missing operating disclosure make the equity case highly price-sensitive.

Flink

Track: Flink looks materially healthier than most quick-commerce peers after surviving the category reset and claiming EBITDA profitability in core markets, but the current ~$0.9B-$1.0B private band already reflects much of that recovery while labor, retention, and cash-flow proof remain incomplete.

Valuation

$900M

Growth

20%

boAt

boAt is a scaled and now-profitable Indian consumer-hardware brand with real public-market potential, but governance overhang, service-quality friction, and category commoditization make it a price-disciplined track rather than a high-conviction buy.

Valuation

$1.5B

Revenue run-rate

$370M

Zerodha

Zerodha is a premium private brokerage platform with elite profitability and strong strategic positioning, but the current public valuation anchor looks fair rather than obviously cheap without better disclosure and transaction-quality price evidence.

Valuation

$8.2B

Growth

-11.5%

FPL Technologies (OneCard)

OneCard looks like a real scaled Indian consumer-fintech asset, but the correct current stance is track rather than commit, because regulatory remediation and private risk metrics matter more than brand strength alone.

Valuation

$1.4B

Growth

163%

Molbio Diagnostics

Molbio Diagnostics has genuine business quality — profitable FY25 operations, WHO-backed TB credibility, and unusual field-deployment relevance — but the right recommendation remains Track until IPO pricing, concentration, and service-quality disclosure catch up with the story.

Valuation

$1.6B

Revenue run-rate

$122M

Growth

21.98%

Purplle

Purplle is strategically interesting and credibly scaled, but public evidence still supports a research-more stance because disclosure, service quality, and forward financial verification remain incomplete.

Valuation

$1.3B

Revenue run-rate

$82M

Growth

43%

Tyme Group

Tyme Group is a structurally credible emerging-market neobank with proven South African unit economics and Nubank's strategic endorsement, but information asymmetry — no consolidated group audited financials, unconfirmed Philippine profitability, and partial cap table disclosure — prevents a high-confidence buy recommendation on publicly available evidence alone; track and request group financials before committing.

Valuation

$1.5B

Growth

29%

Kry

Kry has built one of Europe's more credible hybrid-care platforms, but unresolved financing terms, labor-heavy economics, and channel opacity keep the stock in track territory rather than buy territory.

Revenue run-rate

$232M

ARR

$232M

Growth

13.3%

Octopus Energy

Octopus Energy combines the UK’s leading digital green retailer with a globally scaled utility software platform; the opportunity is credible, but underwriting still hinges on unverified Kraken economics and regulatory execution.

Valuation

$9B

Revenue run-rate

$15.8B

EasyPost

EasyPost appears to be a real and strategically relevant shipping infrastructure company, but the reported 2026 unicorn valuation is not well enough supported by public evidence to justify a clean investment recommendation.

Valuation

$1.5B

Aether Intelligence

Aether looks like a serious regional enterprise-AI company, but the current $1B valuation already prices in premium outcomes that the public evidence cannot yet fully prove.

Valuation

$1B

Revenue run-rate

$50.4M

ARR

$50.4M

NRR

158%

Digital Edge

Digital Edge appears strategically credible and likely valuable, but public evidence still supports RESEARCH-MORE rather than a conviction-priced entry at an unknown valuation.

Erebor Bank

Research-more: Erebor may become a valuable frontier-sector banking franchise, but current public evidence does not yet justify underwriting the reported $8B valuation talk without deeper diligence and better price discipline.

XREAL

XREAL is the most credible independent mass-market AR-glasses vendor in the current public record, but the present valuation already prices in optionality that still needs proof.

Valuation

$1B

Revenue run-rate

$72M

Micro Connect

Track: Micro Connect may be building a genuinely differentiated market for small-business cashflow investing, but public disclosure is still too thin to underwrite the story at any price.

Valuation

$1.7B

Fresh Life Cold Chain

Fresh Life Cold Chain is a scaled Chinese cold-chain unicorn with real infrastructure and digital-control depth, but the current public mark already prices in substantial execution success.

Valuation

$1.6B

Revenue run-rate

$1.4B

Zhiyuan Robot

Track: Zhiyuan is a credible China humanoid frontrunner with real deployment proof, but the current public mark already prices in more confidence than the public economics can yet support.

Valuation

$2.1B

Simile

Compelling synthetic-behavior platform with marquee enterprise proof and elite research lineage; current $2B price is plausible but full given unresolved economics, governance, and terms disclosure.

Valuation

$2B

Moqi Intelligent Technology

Morphi is a credible company to track because the market, founders, and investor syndicate are all real strengths, but the current near-unicorn price already discounts major execution wins that have not yet been demonstrated in public.

Valuation

$966M

Myricx Bio

A scientifically differentiated but still binary preclinical ADC payload platform whose $1.5B announced Novartis exit validates strategic scarcity more than clinical proof; worth tracking, but not treating as de-risked.

Valuation

$1.5B

Quantum Space

Quantum Space pairs a differentiated national-security mobility thesis with real government traction, but the announced $1.2B valuation still sits ahead of flagship flight proof, funded- backlog transparency, and mature servicing-market evidence.

Valuation

$1.2B

Collate

Category-leading promise, but public fundamentals lag the valuation: compelling workflow wedge with a stretched current price pending KPI proof.

Valuation

$1B

EigenQ

EigenQ sits in an attractive quantum-safe infrastructure wedge, but the announced ~$3B SPAC valuation still outruns the public evidence base and supports RESEARCH-MORE rather than conviction buying.

Valuation

$3B

Elroy Air

Elroy Air has a differentiated and strategically relevant autonomous cargo-aircraft thesis with real partner and customer validation, but the current public record still leaves too much contract, operating, and financial opacity to underwrite the announced $1 billion valuation with high conviction.

Valuation

$1B

Eliyan

Eliyan appears strategically relevant and technically differentiated, but the visible unicorn valuation still runs ahead of the visible operating proof.

Valuation

$1B

PatSnap

PatSnap looks like a real scaled innovation-intelligence platform with meaningful ARR and customer proof, but public-only evidence still supports a research-more stance because the rumored IPO valuation appears full before retention, margin, governance, and float-structure details are proven.

Valuation

$2B

ARR

$100M

Growth

20%

Foodics

Foodics is a credible MENA restaurant-tech champion, but the public file still supports tracking rather than buying.

Growth

29%

Ajaib

Ajaib combines real retail scale, strong product breadth, and credible growth signals, but public evidence still leaves too much uncertainty on consolidated financial quality, customer-quality metrics, and risk-adjusted valuation to underwrite the unicorn mark aggressively.

Valuation

$1B

Revenue run-rate

$142.1M

Growth

152%

Interswitch

Interswitch appears to be a durable Nigerian payments infrastructure franchise with real revenue and renewed profitability, but the public record still favors further diligence over paying materially above its stale 2019 unicorn anchor.

Valuation

$1B

Revenue run-rate

$121M

Growth

50%

Carousell

Carousell has improved enough operationally to justify serious investor engagement: FY25 revenue reached US$141M, recommerce is now 45% of revenue, and the group reported positive EBITDA. However, the company still sits in a difficult middle ground between premium private recommerce winners and cheaper public resale comps, while trust, competition, and disclosure gaps keep the 2021 unicorn valuation from becoming an easy premium case. The right posture is conditional: track closely, lean in on diligence, and only upgrade conviction if FY26 proves durable, risk-adjusted profitability.

Valuation

$1.1B

Revenue run-rate

$141M

Growth

18%

Moneybox

Moneybox is a rare profitable consumer fintech at real UK scale, but the July 2026 PISCES-derived unicorn mark looks fair rather than clearly attractive without post-transaction and data-room proof.

Valuation

$1.1B

Cover Genius

Cover Genius has credible global embedded-insurance scale and real partner proof, but public disclosure is still too thin on economics, concentration, and security terms to underwrite the July 2026 USD 1.9B mark with high confidence.

Valuation

$1.9B

Growth

50%

Reliable Robotics

Reliable Robotics looks like a serious autonomous aviation leader, but the current private mark already prices in substantial certification and commercialization success.

Valuation

$1B

Kraken Technology Group

Kraken has real sovereign customer proof and strategic sector positioning, but the July 2026 unicorn valuation still depends on fundamentals the public record does not disclose.

Valuation

$1B

Kela Technologies

Kela looks like a strategically important early defense-platform company with real deployment proof and exceptional financing momentum, but the current private valuation already discounts a great deal of future execution that public evidence does not fully underwrite.

Valuation

$1.2B

Assured

Research-more: Assured looks like a real and strategically interesting vertical-AI company, but public valuation support trails public company-quality signals.

Valuation

$1B

Revenue run-rate

$22M

ARR

$22M

Base Power

Base Power has a differentiated residential-battery plus retail-power model and real early Texas traction, but the latest $4B mark already prices in durable ERCOT economics and successful multi-state replication that public evidence does not yet prove.

Valuation

$4B

Castellion

Track: Castelion has credible strategic importance and real government traction, but public evidence still does not justify aggressive pricing without deeper diligence on economics, conversion, and factory execution.

Valuation

$2.8B

Main Func

Main Func remains investable on public evidence, but only for investors willing to do proof-heavy diligence and maintain price discipline against a valuation that has already stepped up aggressively.

Valuation

$2.6B

Revenue run-rate

$250M

ARR

$250M

Morpho Labs

Morpho has a credible claim to becoming a core rail for embedded onchain credit, but public valuation underwriting still hinges on unverified monetization and concentration assumptions.

Valuation

$2B

Crimson Education

Research-more: Crimson has real scale, a differentiated multi-product education portfolio, and a plausible claim to its unicorn mark, but the lack of audited economics and cap-table transparency keeps the current valuation from being a conviction-priced entry.

Valuation

$1B

Revenue run-rate

$100M

Coda Payments

Coda is a strategically differentiated gaming-native payments and commerce platform with real scale and useful post-Recharge optionality, but the stale US$2.5 billion anchor is only investable with pricing discipline because public disclosure on combined economics remains thin.

Valuation

$2.5B

Princeton Digital Group

Research more: PDG is a serious APAC digital-infrastructure platform with fresh unicorn-plus validation, but public evidence is still too thin on realized economics and security terms to underwrite a narrow valuation.

Valuation

$4B

Antares Nuclear

Antares has delivered a rare hardware milestone and a government-anchored orderbook, but a ~$1.3B pre-revenue valuation prices in flawless execution against nuclear's long history of delay.

Valuation

$1.3B

Crystalys Therapeutics

Crystalys has a credible late-stage gout asset and ample funding, but the absence of public price and launch economics still supports TRACK rather than a priced-in buy call.

Neo Security

Neo is an intriguing, well-funded agentic-security startup with a coherent product thesis, but the public record is still too thin on customer proof and price clarity to justify more than a track stance.

Locus Robotics

Watch: Locus has real enterprise traction and a plausible route to higher-value automation, but public evidence still does not justify paying the last private benchmark without an opacity discount and deeper financial diligence.

Valuation

$2B

Revenue run-rate

$180M

ARR

$180M

AdvanCell

Track AdvanCell rather than underwriting aggressively today: the company looks strategically valuable, but the public record is still too opaque for precise valuation confidence.

Treeline Biosciences

Treeline pairs Loxo-caliber founders, a broad multi-modality platform and >$900M of pro-forma cash with a complete absence of human proof-of-concept, making its ~$2.5B implied valuation a cash-supported option that only 2027 clinical data can re-rate.

Valuation

$2.5B

Revenue run-rate

$0M

AI21 Labs

Track: AI21 has real technology, real customer proof, and a plausible Maestro-led wedge, but the latest visible unicorn mark offers too little public margin of safety for a higher-conviction recommendation.

Valuation

$1.4B

DriveNets

DriveNets looks like one of the more credible late-stage network-infrastructure stories in the market, but the June 2026 $8.5 billion valuation still appears stretched until public or private diligence fills in the missing revenue and margin denominator.

Valuation

$8.5B

Pasqal

Pasqal is one of Europe’s most credible quantum-computing platforms, but the current ~$2B valuation still needs materially more revenue, renewal, and production proof to look attractive.

Valuation

$2B

Lila Sciences

Lila is one of the best-capitalized AI-for-science startups in market, but the current valuation already assumes scientific and commercial proof that the public record has not yet fully shown.

Valuation

$1.3B

Vast

Category leadership in AI 3D creation and credible adoption make Vast worth tracking, but the reported unicorn valuation still outruns public revenue disclosure and carries real China-risk haircuts.

Valuation

$1.5B

Keyuan Petrochemicals

Keyuan looks like a real industrial unicorn rather than a paper one, but the current public record supports deeper diligence more than it supports conviction pricing.

Valuation

$1.1B

Ionic Digital

Ionic has crossed the threshold from distressed mining successor to credible AI infrastructure platform, but the current valuation still requires patience because customer diversification and post-listing execution are not yet proven.

Valuation

$2.4B

Revenue run-rate

$193M

ARR

$251M

Ominimo

Ominimo has a rare mix of speed, underwriting signal, and capital-light expansion, but the current unicorn valuation still outruns the quality of public disclosure.

Valuation

$1.6B

Revenue run-rate

$350M

Kurly

Kurly has proven its dawn-delivery model structurally profitable after 10 years of losses, but razor-thin margins and Coupang's dominant scale leave IPO-stage upside contingent on sustaining Q1 2026's exceptional growth momentum.

Valuation

$1.9B

Revenue run-rate

$3B

Growth

28.4%

Pigment

Pigment is a credible enterprise xP&A platform with strong product narrative and elite customer logos, but insufficient public financial disclosure to support a buy at the last disclosed $1B+ valuation — research-more pending data room access

Valuation

$1B

DataSnipper

DataSnipper has built a defensible Excel-native AI audit automation platform with Big Four validation and Microsoft partnership, but its $1B valuation requires sustained AI-tier ARR acceleration and carries material Microsoft Copilot competitive risk

Valuation

$1B

ARR

$44.5M

PointClickCare

PointClickCare is the dominant LTPAC EHR platform with structural retention moat and active IPO preparation — a compelling business at the right price, but unresolved revenue baseline ($480M–$673M), undisclosed NRR, and information-blocking litigation require resolution before committing at the $5B secondary market price.

Valuation

$5B

Revenue run-rate

$480M

Dongchedi

Dongchedi has dominant scale in China's automotive content vertical and a defensible ByteDance distribution moat, but opaque financials, heavy parent dependency, and a challenged comparable set make the $3 billion private valuation only fair at current transparency. The pending Hong Kong IPO is the key catalyst; materially higher conviction requires revenue disclosure.

Valuation

$3B

Flex

Flex is a credibly fast-growing fintech unicorn with a differentiated owner-finance thesis, but the $1.2B valuation prices in platform execution that is not yet fully proved in the public record.

Valuation

$1.2B

Revenue run-rate

$100M

VerSe Innovation

VerSe Innovation is a real scaled Bharat media asset with improving FY25 economics, but stale price discovery, governance overhang, and thin product- level disclosure keep the investable call at track rather than buy.

Valuation

$2.9B

Growth

88%

Newsela

Newsela looks like a real district-scale instructional platform with enough ARR and customer proof to merit active tracking, but the public record still supports price discipline rather than a fresh buy at the historical unicorn reference.

Valuation

$1B

ARR

$109M

Twenty Technologies

Twenty has a real strategic-defense cyber story and enough customer proof to merit serious diligence, but the latest $1.2B private mark is still difficult to underwrite from public evidence because the financial denominator remains opaque.

Valuation

$1.2B

Cedar

Cedar appears to be one of the stronger private patient-financial-engagement platforms, but public evidence still leaves too much uncertainty around current financial quality and pricing to support a high-conviction premium valuation call.

Valuation

$3.2B

Path Robotics

Path Robotics has credible product, customer, and market proof, but the public record is still too opaque on economics and current pricing to support price-insensitive underwriting.

Ai.tech

Ai.tech appears to own strategically relevant ad-tech assets and may directionally merit unicorn status, but weak operating disclosure keeps the investment case in research-more territory.

Valuation

$1.5B

Yubi

Yubi is a strategically credible debt-infrastructure unicorn, but the current private mark is best approached with discipline because public proof on monetization, concentration, and regulatory cleanliness still lags the strength of the platform story.

Valuation

$1.5B

Revenue run-rate

$79M

Vivriti Capital

Vivriti looks like a real scaled franchise in Indian mid-market credit, but leverage, concentration, and incomplete post-demerger transparency keep the current valuation in the fair rather than obviously attractive bucket.

Valuation

$1.7B

Growth

28.9%

Celero Communications

Celero Communications is a technically credible coherent DSP startup with Alphabet backing and elite semiconductor founders, but is pre-scale with unverified revenue and high execution risk at a ~$1B entry valuation.

Valuation

$1B

Veeam Software

Veeam appears to be a scaled, high-quality private data-resilience leader, but the public record still does not fully justify paying above the known $15B secondary mark without targeted confirmatory diligence.

Valuation

$15B

ARR

$1.7B

Growth

18%

Talkdesk

Talkdesk has real scale, enterprise customer proof, and a credible AI-led product stack, but the public evidence still does not justify high-conviction underwriting at its historical $10B private mark.

Valuation

$10B

ARR

$420.1M

Growth

41%

HiBob

HiBob has credible scale, broad product ambition, and strong strategic logic, but investors should treat the current unicorn mark as premium and only partially underwritten until newer audited metrics surface.

Valuation

$2.5B

ARR

$121.7M

Checkmarx

Checkmarx has real enterprise scale and contemporary unicorn evidence, but public data is still too incomplete to underwrite a $2.5B+ target with high conviction.

Valuation

$2.5B

ARR

$150M

Icertis

Icertis looks like a real late-stage enterprise software asset with durable category demand and strong ecosystem leverage, but current valuation still requires disciplined diligence because disclosure remains partial and governance continuity is newly important.

Valuation

$5B

ARR

$300M

Growth

25%

Flow

Flow has real operating substance and unusual access to capital, but the public record still does not justify high-conviction comfort on governance, unit economics, or a $2.5B private valuation.

Valuation

$2.5B

Cathedral

Cathedral pairs elite-investor backing and unusual founder access to the US defense-cyber buyer with an extraordinary $1.4B pre-revenue valuation and acute political, execution, and verification risk.

Valuation

$1.4B

Atoms

Atoms is a boldly capitalized, Kalanick-led bet on industrial automation whose reported ~$10B valuation runs ahead of the private, unproven divisional economics visible in public sources.

Valuation

$10B

Meshy

Meshy is the scale and mindshare leader in AI 3D generation with an exceptional user base and growth, but its ~$1.5B valuation prices in roughly 50x ARR against unproven monetization, intensifying big-tech and open-source competition, and a China-linked investor base.

Valuation

$1.5B

Revenue run-rate

$30M

ARR

$30M

Growth

1,100%

Candid Health

Fast-growing, AI-native RCM platform with exceptional company-reported growth and retention, but an undisclosed valuation and largely private financials warrant deeper diligence before underwriting.

Growth

190%

NRR

180%

Cabify

Cabify looks operationally stronger than many mobility peers because public evidence supports scale and profitability, but exact valuation confidence remains limited by stale pricing anchors, regulation, and thin structural disclosure.

Valuation

$1.4B

Revenue run-rate

$858M

Factorial

Factorial looks like a real European category leader in SME HR software, but the $2.5B valuation is best underwritten as a premium-growth bet rather than as a low-risk or fully transparent financial story.

Valuation

$2.5B

Revenue run-rate

$100M

ARR

$100M

CloudWalk

CloudWalk looks undervalued relative to its current revenue scale and profitability, but the investment case depends on validating the durability of its FIDC-backed funding and credit engine.

Valuation

$2.2B

Revenue run-rate

$990M

ARR

$1.3B

Growth

99%

Betterfly

Betterfly has enough strategic substance to merit continued diligence, but not enough public economics disclosure to support a confident pricing call.

Valuation

$1B

Revenue run-rate

$72M

ARR

$72M

NotCo

NotCo has a credible AI-platform differentiation story, but current valuation support remains too opaque for anything stronger than track.

Valuation

$1.5B

Revenue run-rate

$75M

Octopus Energy Group

Octopus Energy pairs the UK's highest-NPS energy retailer with a $8.65B AI utility platform; entry at $9B is defensible if Kraken ARR and churn are verified — but the data-room gaps are blocking.

Valuation

$9B

Revenue run-rate

$15.8B

Valo Health

Valo Health has assembled compelling strategic-deal momentum with Novo Nordisk and Merck KGaA but still faces a long financing-disclosure gap, unproven approval path, and a visible pipeline failure.

Valuation

$2.8B

ZeroAvia

ZeroAvia has assembled one of the stronger public strategic stacks in hydrogen-electric aviation, but the investable question is still pricing and milestone conversion rather than company quality alone.

Crusoe Energy Systems

Crusoe has built a differentiated power-first AI infrastructure platform, but the post-Series-E valuation already assumes successful hyperscale execution that public evidence does not yet fully underwrite.

Valuation

$10B

Svante Technologies

Svante holds the world's only solid-sorbent carbon-capture filter gigafactory and the strongest strategic investor syndicate in its category, but is pre-revenue with all commercial projects pre-FID and no disclosed financials, warranting a research-more stance pending FID confirmations and greater disclosure.

Psibot

Psibot pairs an elite embodied-AI team, a platform-licensing model, and marquee strategic backers with a $1.48B unicorn price — but with no disclosed revenue, self-reported benchmarks, and China-specific regulatory exposure, the valuation is an option on execution that diligence must underwrite before committing at the current mark.

Valuation

$1.5B

SiMa.ai

SiMa.ai is a credible, well-backed Physical AI silicon company, but its reported roughly USD1.4 billion valuation prices execution that is not yet independently visible and sits far above public edge-AI comparables, so the disciplined stance is research-more pending audited financials.

Valuation

$1.4B

Prague Technology

Exceptional founder credentials and strong market timing create a compelling story at the low end of global world-model valuations, but complete pre-product status, China risk premium, and GPU export controls support a neutral rather than buy recommendation.

Valuation

$2B

MGT

MGT is a credible and differentiated SLED technology platform with institutional validation at unicorn scale, but the investment case requires private diligence to verify audited revenue, debt structure, and organic growth quality before a buy recommendation can be supported.

Valuation

$1.3B

Revenue run-rate

$400M

Augustus

Exceptional regulatory asset (OCC charter) justifies attention; conditional invest pending FDIC approval confirmation, technology diligence, and management depth validation.

Valuation

$1B

Matchroom

Structurally moated UK sports promoter at a full valuation — exceptional business quality, insufficient margin of safety at £1B+ entry.

Valuation

$1.4B

Revenue run-rate

$286M

SiliconFlow

SiliconFlow looks like a real and increasingly important China-based inference platform, but the disclosed June 2026 price already asks investors to underwrite future margin improvement, enterprise durability, and supply / compliance execution that the public record still does not fully prove.

Valuation

$1.2B

Evoken

Evoken has rare scale for a young AI video and creative-software company, but public underwriting still depends on unaudited ARR, evolving regulation, and third-party model economics.

Valuation

$2B

Revenue run-rate

$300M

ARR

$300M

Growth

3,000%

Aerospace Yuxing

Aerospace Yuxing has real product and customer proof, but the public record still supports tracking the company more than paying peak-narrative pricing.

CuspAI

Track: CuspAI has a high-quality strategic story and credible early proof, but the June 2026 $2.6B mark already assumes commercial success that is not yet visible in public economics.

Valuation

$2.6B

Bulage

Bulage may become an important China embodied-AI platform, but public evidence still does not justify underwriting the reported $2B valuation as a buy today.

Valuation

$2B

Entrepreneurs First

EF's $1.3B unicorn valuation is well-anchored by $1.44B implied portfolio equity, validated by world-class informed investors, and driven by a genuinely differentiated pre-idea talent investor model — but the Matt Clifford conflict-of-interest risk and absence of public financial metrics represent material diligence gaps that must be resolved before institutional commitment.

Valuation

$1.3B

Advanced Manufacturing Company of America

Well-timed defense-industrial roll-up with real assets and top-tier backing, but financially opaque — research more rather than underwrite the ~$1.1B price on public evidence.

Valuation

$1.1B

Twelve Labs

Strategically credible video-AI unicorn, but financially opaque — track / research more rather than buy at a presumed ~$1B entry.

Valuation

$1B

Heirloom Carbon Technologies

A credible, marquee-backed limestone-DAC leader whose thesis rests on unproven unit economics, heavy subsidy dependence, and an unverified valuation — a track / research-more, not a buy.

Humanoid

A fast-executing European humanoid robotics leader with elite partnerships and a large pre-order book, but a $1.35B pre-revenue valuation that rests on still-unproven commercial conversion.

Valuation

$1.4B

Corgi

Corgi is a high-conviction Series B1 insurtech with extraordinary revenue traction and a compelling full-stack carrier model, but a stretched $2.6B valuation, limited claims history, and unaudited financials warrant disciplined diligence before further investment.

Valuation

$2.6B

ARR

$40M

Zilch

Zilch looks like a real and differentiated UK fintech platform, but the current private valuation still requires selective, price-sensitive underwriting rather than a clean buy call.

Valuation

$1B

Property Finder

Property Finder appears to be a strong regional property-marketplace asset with credible profitability signals and product breadth, but private-financial opacity keeps the current stance at research-more rather than buy.

Satispay

Research-more: Satispay has built real network scale and platform breadth, but the current unicorn valuation still runs ahead of public disclosure quality.

Growth

80%

Zyphra

Zyphra has unusually strong public technical and partner evidence for a private AI startup, but its customer proof and economics disclosure are still too thin to justify price-insensitive underwriting. The report supports a research-more / track stance: constructive near the last supported unicorn mark, but cautious toward rumored 2026 step-up pricing until customer and financial proof improves.

Valuation

$1B

ARR

$8.8M

Pump

Pump appears to be a credible and differentiated cloud-cost-optimization company with real customer proof, but the reported valuation is stretched relative to the public evidence available on revenue quality, margin durability, and concentration.

Valuation

$1.5B

Revenue run-rate

$15.2M

ARR

$15.2M

SHAREBOT

SHAREBOT addresses a real adoption pain point in robotics, but the company is too young and too lightly disclosed to justify strong conviction at a unicorn valuation.

Valuation

$966M

Origin Quantum

Origin Quantum looks like one of China’s most credible full-stack quantum infrastructure companies, but incomplete financial disclosure, customer-transparency gaps, fault-tolerance uncertainty, and geopolitical friction keep the investment stance at research-more rather than conviction buy.

Valuation

$2.1B

DeepSeek

Track DeepSeek for technical leadership and demand momentum, but underwrite cautiously because opaque financials and elevated geopolitical, IP, and governance risks make current pricing hard to justify.

Valuation

$50B

StepStar

StepStar is a technically credible, well-capitalized member of China's foundation-model "Big Six" with a distinctive multimodal and AI-terminal strategy, but undisclosed financials and contested, steeply escalating valuation marks keep it a research-more rather than a buy.

Valuation

$10B

Lighter

Lighter has enough public scale, technical differentiation, and investor validation to merit serious continued diligence, but the $1.5B valuation is not fully cleared by public evidence because revenue quality, customer concentration, and regulatory durability remain under-disclosed.

Valuation

$1.5B

Recursive

Recursive looks strategically important and technically credible for its age, but the current $4.65 billion valuation is not publicly underwritten enough to support a buy call.

Valuation

$4.7B

Arena

Arena looks like a real category leader in AI evaluation, but public evidence does not yet justify underwriting the reported $1.7B valuation with buy-level conviction.

Valuation

$1.7B

Revenue run-rate

$100M

Virta Health

Virta appears to be one of the higher-quality private metabolic-health companies in the market, but the available public record still supports tracking the business rather than underwriting a fresh entry at roughly $2 billion.

Valuation

$2B

Revenue run-rate

$160M

ARR

$160M

Growth

80%

Mirakl

Mirakl has the scale and profitability of a serious late-stage software asset, but the visible private mark still looks stretched enough that the right public-evidence verdict is track, not buy.

Valuation

$3.5B

ARR

$218M

Growth

23%

Postman

Postman has clear category leadership in API collaboration and workflow context, but public evidence is still too contradictory on revenue and too thin on governance and capital structure to underwrite the company confidently at or near its 2021 peak valuation.

Valuation

$5.6B

Cockroach Labs

Cockroach Labs looks like a real late-stage infrastructure winner candidate, but the current private-market price appears stretched relative to public evidence on revenue and efficiency.

Valuation

$6.9B

ARR

$128.3M

Aledade

Aledade looks like one of the strongest private physician-led value-based-care platforms, but the visible 2026 valuation still appears stretched relative to public comps once debt, policy risk, and disclosure gaps are considered.

Valuation

$3.5B

Revenue run-rate

$1B

ARR

$750M

Alentis Therapeutics

Alentis has assembled a credible first-in-class CLDN1 platform across oncology ADCs and fibrosis, backed by a large Series D and visible clinical momentum. The strongest public signals are target coherence, high-quality financing, and multicenter trial activation; the weakest are valuation transparency, cash/runway disclosure, and human efficacy proof. A Track / research-more stance is warranted until priced-round terms or clean human data materially reduce underwriting uncertainty.

Destinus

Destinus has credible product, partner, and defense-demand momentum, but public evidence does not yet justify underwriting the rumored >€5B 2026 valuation.

Kairos Power

Kairos Power is one of the strongest strategic platforms in advanced nuclear, but public-only evidence supports a track stance rather than a buy because valuation and economics remain under-disclosed while first-of-a-kind execution risk stays high.

Ledger

Ledger is strategically compelling and plausibly worth several billion dollars, but the public record still supports a track / research-more posture rather than an aggressive premium underwriting call.

Valuation

$4B

IM Motors

IM Motors looks like a real premium Chinese EV contender, but the current public evidence still supports a watch / track call rather than paying up for a fully validated unicorn-quality valuation.

Valuation

$4.2B

Neo Fusion

Neo Fusion is strategically important inside China's fusion roadmap, but thin disclosure, unproven commercialization, and high milestone risk keep the recommendation at research-more with medium confidence and an unknown valuation stance.

Kin Insurance

Kin appears to be a real specialty-insurance winner with credible revenue scale, renewal momentum, and differentiated catastrophe-market positioning, but the current $2B mark already prices in meaningful future execution while carrier-level and financing-term disclosure remain too thin for a clean yes.

Valuation

$2B

Revenue run-rate

$226.4M

Growth

29%

Oxylabs

Oxylabs looks like a real AI-era web-data infrastructure winner, but the current $3.6B mark already prices in meaningful quality and leaves too little public-evidence edge for a buy call.

Valuation

$3.6B

Revenue run-rate

$350M

ARR

$350M

OriCell Therapeutics

OriCell is one of the more credible China-origin clinical-stage CAR-T stories in 2026, with real financing momentum and meaningful product milestones, but the public evidence does not support underwriting a hidden unicorn valuation or a buy call. The right posture is research-more: track the company closely, demand terms-level diligence, and re-engage on a disclosed price-bearing round or a stronger proof point.

Fever

Track: Fever looks like a real scaled category leader with strong partner proof and plausible operating leverage, but the current private valuation already prices in meaningful success and remains only conditionally supportable without private revenue, retention, and concentration data.

Valuation

$1.8B

Quwan

Quwan looks like a real scaled gamer-social asset with unusually strong historical profitability, but public disclosure is still too stale to underwrite the old unicorn mark with high conviction.

Valuation

$1.1B

Growth

-5.2%

Unisoc

Unisoc is a scaled private Chinese fabless chip vendor with meaningful global share in value-tier smartphone silicon and active IPO momentum, but governance history, geopolitical risk, and incomplete financial disclosure support a TRACK recommendation rather than a buy call.

Valuation

$9.8B

Revenue run-rate

$2B

Yangtze Memory Technologies

YMTC is strategically important and commercially real, but sanctions, capital intensity, and opaque earnings still cap conviction at current valuation talk.

Valuation

$22B

Envision Energy

Track: Envision Energy is strategically important and already very large, but disclosure, geopolitics, and capital-intensity risks keep the public-evidence call at TRACK with medium confidence.

Valuation

$15B

Revenue run-rate

$11.1B

WeDoctor

WeDoctor appears to be a real, strategically important China digital-health platform, but the last widely cited private valuation looks expensive relative to public-comparable evidence and current disclosure quality.

Valuation

$6.7B

Revenue run-rate

$857M

Growth

70%

Spectro Cloud

Spectro Cloud appears strategically relevant in AI infrastructure management, but the current $1B-plus private valuation is better treated as a research-more situation than a buy because public economic proof is still incomplete.

Valuation

$1B

Earendil Labs

Earendil looks like a real AI-biologics platform with rare blue-chip validation, but the current unicorn mark still demands more proof than the public record provides.

Valuation

$1B

Atom Computing

Atom is one of the most credible neutral-atom quantum platforms, but a $2.06B private valuation on sparse public economics still supports RESEARCH-MORE rather than a conviction-priced entry.

Valuation

$2.1B

Lumin Digital

Lumin looks like a credible scaled digital-banking platform, but public disclosure is still too thin to underwrite the current private-market mark with high conviction.

Valuation

$1.6B

Fora

Fora has built credible category traction in advisor-enabled travel and a differentiated AI-product narrative, but the current $1 billion valuation is still difficult to underwrite from public evidence because the revenue, margin, and cohort-quality denominator remains opaque.

Valuation

$1B

Magic AI

Magic has genuine frontier-model upside in code generation, but public proof remains too thin to justify aggressive entry at the last cited $1.5B mark.

Valuation

$1.5B

Emergent

Emergent has real breakout growth and a valuation that is supportable in context, but the public record still points to TRACK rather than a high-conviction buy.

Valuation

$1.5B

Revenue run-rate

$120M

ARR

$120M

Walden Robotics

Research-more: Walden may be one of the strongest new industrial physical-AI entrants, but the current $1.1B seed valuation is too proof-light to underwrite confidently from public evidence.

Valuation

$1.1B

SPIC Hydrogen Energy

SPIC Hydrogen Energy looks strategically stronger than many hydrogen peers, but the public record is still too thin to justify aggressive entry above the last disclosed CNY13B private mark.

Valuation

$1.9B

Liblib

Fast-growing Chinese AI creative-platform unicorn with exceptional ARR growth, but valued on unaudited metrics and exposed to content-safety, copyright and aggregator-margin risks.

Valuation

$2B

Revenue run-rate

$300M

ARR

$300M

Growth

3,000%

D360 Bank

A fast-growing, state-backed Saudi digital bank whose full ~US$1.6B valuation rests on undisclosed unit economics — attractive to watch, premature to underwrite with conviction.

Valuation

$1.6B

Silicon Box

A rapidly scaling, technically credible chiplet-packaging unicorn with record yields and a marquee founding team, offset by near-total financial and customer opacity, extreme capital intensity, and a stretched ~US$1.55B private mark.

Valuation

$1.6B

Orca Bio

A scientifically validated, first-in-class Treg cell therapy with a strong pivotal trial, but priced at a $1.2B mark against a narrow initial label, high manufacturing intensity, and an entirely unproven commercial ramp.

Valuation

$1.2B

PixVerse

PixVerse has achieved a >$2B valuation on real product momentum, strong user growth, and world-model optionality, but the absence of public revenue disclosure and fierce AI-video competition keep the current mark in track territory.

Valuation

$2B

Super.com

Super.com is one of the more compelling consumer fintech stories in the 2026 private market — profitable, growing at 50%, and building a membership flywheel — but investors need segment economics before underwriting the 6x revenue valuation with high confidence.

Valuation

$1.2B

Revenue run-rate

$200M

Growth

50%

Pulumi

Pulumi looks like a real platform-engineering winner in the making, but the current late-stage valuation case still depends on private metrics and round verification that are not visible publicly.

Valuation

$1.5B

Castelion

Castelion combines rare DoD demand pull, credible founder-market fit, and a manufacturing-first thesis that could matter if the Pentagon truly shifts hypersonics from boutique programs to mass procurement, but the current ~$2.8B valuation already prices in substantial execution and production success.

Valuation

$2.8B

Field AI

FieldAI combines elite field-robotics talent, strong investor validation, and a differentiated hardware-agnostic embodied AI stack, but the lack of audited financial disclosure and limited named customer proof make the $2B valuation difficult to underwrite from public evidence alone.

Valuation

$2B

Base Power

Base Power has a differentiated residential-battery plus retail-power model and real early Texas traction, but the latest $4B mark already prices in durable ERCOT economics and successful multi-state replication that public evidence does not yet prove.

Valuation

$4B

Omni Analytics

Strong founder-market fit and a coherent governed-semantic platform have produced real enterprise traction, but thin public durability disclosure and rising bundle pressure leave Omni as a track, not buy, at $1.5B.

Valuation

$1.5B

Nextop AI

Nextop AI addresses a real AI-networking bottleneck with unusual founder and investor quality, but the public record is still too thin to justify aggressive entry at the current $4.2B valuation.

Valuation

$4.2B

SenseTime Medical

SenseTime Medical looks strategically promising enough to stay high on the diligence list, but not yet transparent enough to justify a high-conviction buy at its current private-market mark.

Valuation

$1B

Glow

Glow has the ingredients of a serious endpoint AI security company, but the public record is still too thin to underwrite a confident buy at a unicorn valuation.

Valuation

$1B

BioMap

A strategically compelling AI-biotech platform with real partner and customer proof, but still an under-disclosed valuation story.

Quicktron

Quicktron is a strategically credible warehouse-robotics company, but the investment case still depends on research-more diligence and disciplined pricing rather than on narrative momentum alone.

Valuation

$1B

Gokin Solar

Track: Gokin has real scale and global channel proof, but the current CNY14 billion headline mark still looks stretched relative to stressed public peers and the company's limited audited disclosure.

DeepRoute.ai

DeepRoute.ai has become a commercially relevant Chinese intelligent-driving supplier with real deployment scale, but regulatory tightening, customer concentration, and opaque economics keep the recommendation at track rather than buy.

Stardust Intelligence

Stardust Intelligence has achieved genuine early commercial traction with its cable-driven humanoid but must prove manufacturing scale, unit economics, and the durability of its unconventional actuator approach before its aggressive valuation is justified.

Valuation

$1.4B

LimX Dynamics

LimX Dynamics has secured top-tier Chinese strategic and Middle Eastern backing and a >US$1B valuation for its modular legged-robot and humanoid platform, but trails volume leaders Unitree and AgiBot and carries undisclosed financials plus mounting geopolitical risk.

Valuation

$1B

Aira

Aira has built Europe's best-funded residential electrification platform, but must prove its subscription economics can sustain a ~EUR1.8B valuation against a policy-sensitive, still loss-making heat-pump market.

Valuation

$2B

Revenue run-rate

$220M

Palmetto

Palmetto appears to be a strategically interesting private residential clean-energy platform with real scale, repeat financing access, and credible product breadth—but public evidence still leaves enough margin, portfolio-performance, and capital-dependency gaps that the right call is research-more with strict valuation discipline rather than an unconditional buy.

Valuation

$1B

ARR

$75M

Genesis Therapeutics

Track: Genesis has stronger pharma validation than many private AI-drug-discovery peers, but public valuation support is still narrower than bullish premium narratives and the disclosure gap remains material.

Valuation

$806.8M

Dataiku

Dataiku looks like a real late-stage enterprise AI leader with fair current valuation support, but the lack of public margin, retention, and cash disclosure keeps it in track rather than buy territory.

Valuation

$3.7B

Revenue run-rate

$350M

ARR

$350M

Starburst Data

Starburst appears to be a strong private data-infrastructure asset with real ARR, retention, and regulated-customer proof, but public disclosure gaps around retention cohorts, concentration, margins, cash, and round structure make research-more a more defensible call than an unconditional buy.

Valuation

$3.4B

Revenue run-rate

$100M

ARR

$100M

Growth

40%

NRR

130%

Sygnum

Sygnum appears to be a strategically credible regulated digital-asset bank with real institutional proof and scarce regulatory positioning, but public evidence still leaves enough revenue, retention, concentration, and margin gaps that the right call is research-more rather than an unconditional pass.

Valuation

$1B

GI Water as a Service

GI Water as a Service appears strategically credible and commercially worth following, but public evidence is still too thin on economics, governance, and round structure to endorse the current unicorn valuation with comfort.

Valuation

$1B

Inertia

Inertia combines elite inertial-fusion pedigree, unusual launch-stage capital, and real LLNL-linked strategic assets, but public information still does not support a confident valuation mark or customer-conviction underwrite.

Revenue run-rate

$0M

Spiber

Spiber still looks like one of the most strategically interesting climate-materials platforms in Asia, but the 2026 reset means investors should value the surviving option carefully rather than assume the old unicorn thesis still holds.

Valuation

$750M

SmartNews

Research more: SmartNews remains a credible late-stage consumer media asset with real Japan positioning and monetization optionality, but the legacy $2B mark looks stretched until current financial, user, and IPO-readiness evidence improves.

Valuation

$2B

Revenue run-rate

$104.5M

Karrot

Track: Karrot is one of Asia's strongest local-network consumer platforms, but underwriting it above the reported 2025 private mark still requires more disclosure and more proof that ads and international expansion can compound cleanly.

Valuation

$1.7B

Revenue run-rate

$95M

Growth

43%

Kakao Mobility

Kakao Mobility looks strategically important and competitively resilient in Korea, but the public case still deserves a discount for antitrust overhang, sponsor complexity, and thin standalone financial disclosure.

Yanolja

Yanolja combines a valuable Korean travel-platform franchise with a promising higher-margin enterprise software engine, but the frequently cited US$10B valuation looks stretched versus public travel-platform comps and the company’s still-limited disclosure depth.

Valuation

$10B

Revenue run-rate

$717M

Growth

11%

Lead Bank

Track: Lead Bank is one of the few profitable, fast-scaling sponsor banks with genuine marquee-fintech traction and a proven operator-CEO, but BaaS regulatory scrutiny, partner concentration, and a premium ~13.6x revenue valuation warrant close monitoring rather than an unconditional buy.

Valuation

$1.5B

Revenue run-rate

$108M

Growth

48%

8090

Research more: 8090 has a real product, real capital, and a credible regulated-enterprise workflow thesis, but the current valuation already assumes operating proof that public sources do not yet provide.

Valuation

$1B

Prime Intellect

A fast-scaling sovereign AI infrastructure platform with real revenue and customer proof, but still too many valuation-critical unknowns to underwrite at full confidence from public evidence alone.

Valuation

$1B

Revenue run-rate

$100M

Beeline Medicines

Beeline appears to be a strong private lupus-first immunology company with serious capital, credible mechanisms, and multiple shots on goal—but the right current call is research-more because public evidence still does not disclose the valuation, cap table, burn, or retained asset economics needed for price conviction.

LeapXpert

LeapXpert appears to be a credible governed-communications platform with real regulatory relevance, meaningful customer proof, and strong sponsor backing—but public evidence is still too thin on economics and valuation to support a premium-price buy call.

Harbinger Motors

Harbinger has credible capital, customers, and product coherence, but the public record still supports a track stance because the company’s late-stage valuation outruns the disclosure quality available on revenue, margins, and scaled field execution.

Valuation

$1.1B

Proxima Fusion

Proxima Fusion is the strongest European fusion asset on paper — IPP/W7-X heritage, a peer-reviewed stellarator concept, blue-chip strategic backing, and Europe's largest fusion war chest — but it is a pre-revenue science moonshot priced at €2.4B with net energy still unproven and grid revenue more than a decade away, so the right call is to track it closely with venture-style, option-value discipline rather than underwrite it on fundamentals.

Valuation

$2.7B

Neara

Fast-growing category leader in grid digital twins with blue-chip utility traction, but backed by opaque financials and a valuation that looks stretched against estimated revenue.

Valuation

$740M

Revenue run-rate

$7M

Instabase

A technically credible enterprise document-AI platform whose January 2025 down round to ~$1.24B signals valuation reset and competitive pressure, warranting cautious diligence.

Valuation

$1.2B

ARR

$50M

Growth

22%

Oratomic

A scientifically credible but unproven, pre-revenue neutral-atom moonshot priced at ~$1.5B — high-conviction watch item, not yet an underwritable entry.

Valuation

$1.5B

Tandem

Forus has built a real prescription-access network with strong growth and strategic value, but the reported $1B valuation remains hard to underwrite without margin, concentration, and governance disclosure.

Valuation

$1B

Revenue run-rate

$50M

Keyfactor

Keyfactor appears to be a strong private trust-infrastructure asset with real enterprise and government proof, repeated sponsor validation, and broad product relevance—but public evidence still leaves enough ARR, retention, margin, concentration, and structure gaps that the right call is research-more with strict price discipline rather than an unconditional buy.

Valuation

$2B

Stori

Research more: Stori shows enough scale, product breadth, and entity-level profitability to stay actively engaged, but a fair valuation stance is more defensible than a strong buy until cohorts, partner economics, and risk-adjusted durability are clearer.

Valuation

$1.3B

Acko

Acko has built a strategically relevant digital-insurance platform with credible scale, improving financial direction, and a real embedded-distribution edge, but public evidence still shows governance overhang, customer-tail risk, and incomplete unit-economics disclosure, so the current IPO range belongs on a conditional watchlist rather than in the portfolio.

Valuation

$2B

Revenue run-rate

$340M

Growth

34%

Sigma Computing

Sigma Computing looks like a real scale-stage winner in warehouse-native analytics, but the current public file supports a constructive, conditional view rather than a high-conviction underwriting call because valuation-relevant quality metrics remain private.

Valuation

$3B

Revenue run-rate

$200M

ARR

$200M

Growth

100%

Klook

Track: Klook is a real scaled APAC travel marketplace and the ~US$1.4B mark is defensible, but not cheap enough to ignore retention, governance, and cap-table uncertainty.

Valuation

$1.4B

Revenue run-rate

$417.1M

Growth

24.4%

Docplanner

Docplanner has enough scale, workflow depth, and geographic breadth to merit continued diligence, but current public evidence supports a research-more stance because leverage, compliance burden, and opaque financing / retention details keep the valuation from looking clearly attractive.

Valuation

$1B

Growth

25%

KnowBe4

Research more: KnowBe4 has real scale, strong customer proof, and high-quality recurring revenue, but elevated leverage, active risk clustering, and limited private-company disclosure keep the current valuation case only fair rather than clearly attractive.

Valuation

$4.6B

Revenue run-rate

$600M

ARR

$367.7M

Abound

Research more: Abound looks like a credible, profitable, and scaled UK open-banking lender, but exact valuation still depends on private evidence about round terms, debt structure, loan-book quality, and Render economics.

Oasis Security

Oasis Security looks strategically important in a fast-growing identity category, but the current public file supports continued diligence more than outright conviction because valuation-relevant operating metrics remain undisclosed.

Valuation

$700M

StockX

Research more: StockX is clearly a scaled authenticated-resale platform with real brand relevance, but the current public file is still too thin on audited financial quality, trust-cost burden, and cap-table detail to support a high-confidence fresh valuation.

Valuation

$3.8B

Revenue run-rate

$1.4B

Nowports

Real regional logistics platform with meaningful public revenue and customer proof, but still too opaque to justify paying the old unicorn mark without refreshed diligence.

Valuation

$1.1B

Jetti Resources

Research more: Jetti has real strategic value and unusually strong public proof for a mining-tech startup, but the current ~US$2.5B mark already prices in substantial future execution despite sparse public financial disclosure.

Valuation

$2.5B

Revenue run-rate

$11.3M

Expel

Expel looks like a real, premium MDR asset with credible growth and customer proof, but the current valuation should only be underwritten after private confirmation of retention, margins, concentration, and runway.

Valuation

$1B

Revenue run-rate

$142.2M

Growth

67%

Datavant

Research more: Datavant appears to be the leading U.S. healthcare-data connectivity platform, but public evidence is still too thin on current economics to underwrite a premium valuation with high conviction.

Valuation

$7B

Bambu Lab

Bambu Lab is a rare profitable consumer-hardware breakout with real platform potential, but the current ~$10B rumor zone looks stretched relative to public comps and still lacks enough disclosure for a buy call.

Valuation

$10B

Revenue run-rate

$1.4B

Tripo AI

Category leadership in AI 3D creation and credible adoption make Tripo worth tracking, but the reported $1.5B mark still outruns public revenue disclosure and carries real China-risk haircuts.

Valuation

$1.5B

General Intuition

Technically credible frontier AI spinout with a differentiated gameplay-data thesis, but the current $2.3B mark is ahead of public customer and economics proof.

Valuation

$2.3B

EXU

High-conviction investor identity (Sequoia, Goldman, Granite Asia) but every operating metric is private; base-case EV modelling sits below the current $1.2B mark and every scenario carries a wide error band.

Valuation

$1.2B

Flying Tulip

High-profile pre-full-launch DeFi super-app with a novel perpetual-put fundraising primitive, credible SAFT syndicate, and a $1B FDV that is mechanically anchored to the redemption reserve; recommendation is TRACK pending public audit disclosure, MiCA/OFAC compliance stack, and post-subsidy retention data.

Valuation

$1B

Konfío

Konfío looks like a real, scaled SME-finance platform with credible product breadth and institutional support, but unresolved valuation, credit-quality, and license-timing questions keep the posture at track rather than buy.

Valuation

$1.3B

Augment

Augment looks like a serious enterprise AI coding platform with strong customer proof and a plausible near-unicorn valuation, but thin public economics keep the investment posture at track rather than aggressive buy.

Valuation

$977M

Mirador Therapeutics

Mirador combines elite private funding with a credible precision-immunology platform, but the public record is still too opaque on assets, valuation, and commercial readiness to justify a fully priced premium thesis; research-more with medium confidence and high risk.

M-KOPA

Research more: M-KOPA looks like a scaled pan-African fintech with credible unicorn economics, but public evidence still does not justify paying a large premium above roughly $1.7 billion without lender-grade portfolio, cap-table, and governance disclosure.

Valuation

$1.5B

ARR

$400M

Growth

65%

Yassir

Research more: Yassir is a credible North-African super-app with real scale and a visible unicorn mark, but the current public file still does not justify paying the last headline valuation with conviction.

Valuation

$1.4B

Tengden

Tengden has credible engineering depth and category leadership in large Chinese UAVs, but the underwriting case is constrained by losses, concentration, and acute policy risk.

Valuation

$1.7B

Growth

20.3%

Envision AESC

AESC has enough customer and plant proof to matter, but the present public file does not justify premium underwriting without audited revenue, margin, leverage, and cap-table evidence.

Tongdun Technology

Tongdun appears strategically relevant in Chinese and cross-border financial-risk infrastructure, but unresolved legal, disclosure, and valuation questions keep the current case in track / research-more territory.

Valuation

$1B

XAG Technology

XAG combines real product depth, global agricultural automation traction, and a demonstrable profit turn, but underwriting remains constrained by competitive pressure from DJI and limited visibility into normalized long-term margins and valuation.

Growth

9.4%

Volant Aerotech

Research more: Volant is a serious, well-funded passenger-eVTOL contender, but the current unicorn mark looks ahead of the public evidence on economics, contract quality and certification confidence.

Valuation

$1.5B

BrainCo

Research more: BrainCo has real product breadth and financing scale, but the current unicorn price looks stretched until private diligence proves stronger customer quality, regulatory progress, and governance clarity than public materials reveal.

Valuation

$1.3B

Blackpoint Cyber

Blackpoint Cyber looks strategically strong in MSP-first MDR, but public evidence still cannot underwrite a precise valuation.

inDrive

inDrive is a differentiated and clearly scaled mobility platform, but the valuation case is constrained by preliminary financials, live regulatory and labor risk, and incomplete disclosure on cash, unit economics, and cap-table terms.

Valuation

$1.7B

Revenue run-rate

$601.6M

Growth

31%

FINN

FINN has built real scale in car subscriptions, but the 2026 unicorn round already prices in strong execution despite unresolved disclosure, capital-intensity, and service-risk questions.

Fox ESS

Fox ESS is a credible unicorn-scale residential-storage leader with real revenue and shipment momentum, but Europe concentration, regulatory scrutiny, and thin disclosure keep the investment case in track territory rather than making it an obviously mispriced growth asset.

Valuation

$1.4B

Norm Ai

Norm Ai has built a structurally distinctive full-stack legal AI platform targeting financial services institutions, validated by Khosla Ventures and elite institutional co-investors, but material information barriers — undisclosed revenue, unresolved ABA Rule 5.4 compliance structure, and a single named founder — limit full investment conviction without private diligence.

Valuation

$1.2B

Even Realities

Even Realities is credible enough to keep on an active diligence list, but public evidence does not justify paying through the July 2026 $1 billion round without deeper private economics and term verification.

Valuation

$1B

terralayr

Terralayr has real capital, credible utility counterparties, and meaningful German BESS scale, but its undisclosed valuation and thin financial disclosure block a price-sensitive investment call.

Ably Corp.

Research more: ABLY is a scaled Korean fashion-tech platform with credible growth, strategic validation from Alibaba, and improving operating performance, but the current headline price still looks rich relative to commerce-like public comps until private economics and round terms are disclosed more fully.

Valuation

$2.1B

Growth

10.6%

Meril Life Sciences

Meril is a real, scaled Indian medtech platform with disclosed profitability and export reach, but live Myval litigation, heavy capital intensity, and a July 2025 valuation already implying premium medtech multiples support only a Track call.

Valuation

$6.6B

Revenue run-rate

$587M

Growth

40.3%

I-TRACING

I-TRACING is a scaled French and increasingly pan-European MSSP with credible operating proof, historical profitability, and strong sponsor support, but the absence of a clean public current valuation and combined-group margin disclosure keeps the case in track rather than buy territory.

Growth

30%

LINE MAN Wongnai

Research more: LINE MAN Wongnai has real Thai scale, credible ecosystem breadth, and signs of improving profitability, but the current public record is still too thin on audited financial quality, control-transaction terms, and subsidy-normalised cohorts to justify a premium-priced IPO or private entry above roughly THB55 billion.

Safe Security

Safe Security is a credible category leader in enterprise cyber risk management with strong Forrester and analyst validation, but limited financial transparency keeps the $1B+ entry multiple at the borderline of fair-to-stretched without audited unit economics.

Valuation

$1B

Gilmour Space Technologies

Strategically vital, government-backed sovereign-launch champion carrying a unicorn valuation ahead of a proven orbital rocket — high potential, high binary technical risk.

Valuation

$650M

Redo

A broad, fast-growing, AI-forward post-purchase platform with a proven ex-Divvy team and owned international logistics, priced at a $1.25B unicorn mark on undisclosed financials and a regulation-exposed shopper-fee model.

Valuation

$1.3B

Leju Robotics

High-growth humanoid robotics leader with explosive unit sales but pre-profit financials, aggressive IPO valuation, and concentrated competitive market.

Valuation

$600M

Revenue run-rate

$36M

Growth

361%

Square Yards

Square Yards is a fast-growing, newly-minted Indian proptech unicorn with strong revenue growth (48% YoY) and improving profitability (8% EBITDA margin), differentiated by its integrated full-stack model, but facing execution risk from IPO timing, debt structure opacity, and competitive convergence.

Valuation

$1B

Revenue run-rate

$223M

Growth

48%

Sunwoda Electric Vehicle Battery Co., Ltd.

Fast-growing Chinese EV battery challenger with strong OEM relationships but facing intense price competition, margin pressure, and a down-round valuation signal.

Valuation

$3.5B

Revenue run-rate

$2.6B

Growth

24.9%

Noetix Robotics

High-velocity Chinese humanoid robotics pioneer with breakthrough consumer pricing and strong policy alignment, but unproven unit economics and significant bubble risk in an overcrowded market.

Valuation

$1.4B

Beacon Software

Beacon has a credible AI-enabled software-acquisition thesis and exceptional capital access, but public disclosure is still too thin to underwrite the 2026 valuation confidently.

Valuation

$1.4B

The Open Platform (TOP)

High-upside Telegram/TON infrastructure platform with real distribution leverage, but opaque economics and structure keep it in research-more territory at the current unicorn mark.

Valuation

$1B

RedotPay

Research more: RedotPay has credible product-market pull in stablecoin payments and unusually fast fundraising momentum, but the reported $4 billion IPO target looks stretched until audited financials, partner disclosures, and active-user quality metrics become public.

Valuation

$1B

Revenue run-rate

$150M

Galaxy Bot

Galaxy Bot is a strategically credible Chinese embodied-AI robotics contender with real deployment evidence and unusually deep capital backing, but opaque unit economics and concentrated partner risk keep the underwriting case speculative.

Valuation

$3B

Aaru

Aaru has real early proof and category intrigue, but the $1B entry mark still outruns the public economics package.

Valuation

$1B

Navi Technologies

Track: Navi is a scaled Indian fintech with real regulated-product breadth, lending-arm profitability, and a large consumer funnel, but regulatory scar tissue, debt-heavy funding, and unsigned valuation terms keep the case short of a buy recommendation.

Valuation

$1.8B

Growth

19.1%

DexForce

DexForce has enough evidence of real product depth, investor support, and early commercial deployment to merit continued diligence, but the current unicorn valuation outpaces the quality of public proof on audited economics, independent customer durability, and scalable margin.

Valuation

$1.4B

Blip

Blip has credible scale, profitability signals, and dense customer proof, but public evidence still does not reveal the current round price, preference stack, or enough retention and margin detail for a high-conviction buy call.

Growth

40%

Core Automation

Core Automation has elite frontier-AI talent and credible research ambition, but the public evidence remains too thin on product, customers, and revenue to justify high-conviction underwriting at the reported valuation targets.

Valuation

$1B

Stipple Bio, Inc.

A credentialed, well-funded pre-clinical ADC platform with genuine differentiation potential but no data, no disclosed target, and no confirmed valuation — research-more until key facts are shown.

Applied Compute

Track: credentialed founding team and named enterprise traction support a watch position, but undisclosed unit economics and a concentrated customer base require more diligence before a buy call.

Valuation

$1.3B

ModRetro

ModRetro has credible enthusiast product pull and enough capital to attempt a broader physical-IP platform, but public disclosure is still too thin to underwrite the market-reported ~$1B valuation confidently.

Valuation

$1B

Zero Hash

Zero Hash appears to be one of the best-positioned compliance-first digital-asset infrastructure vendors, but the absence of public revenue and concentration data keeps the recommendation at track rather than buy.

Valuation

$1B

RunPod

RunPod has scaled to a reported ~$240M ARR with strong developer adoption and clear cost-positioning in GPU cloud, but limited disclosure and intense infrastructure competition keep the upside balanced by execution risk.

Valuation

$1B

Revenue run-rate

$240M

ARR

$240M

Growth

90%

NRR

120%

QuEra Computing

QuEra is one of the strongest private neutral-atom quantum companies, but public evidence still supports Track rather than Buy because repeatable economics and round terms remain opaque.

Valuation

$1B

Revenue run-rate

$39.9M

ARR

$39.9M

Growth

533%

Element Labs

Element Labs combines elite semiconductor founder pedigree and strong financing momentum, but public proof of customers, economics, and governance still trails its reported >$4B valuation.

Valuation

$4B

CtrlS

CtrlS is India's scaled domestic hyperscale data-center leader, but private-company opacity keeps the current price anchor in the track rather than buy bucket.

Valuation

$5.2B

Revenue run-rate

$180M

Growth

16%

Salla

Salla is a well-evidenced, dominant Saudi e-commerce SaaS platform with real institutional capital, but no disclosed valuation, revenue, or reconciled scale metric supports a price-sensitive call today.

Kopi Kenangan

Kopi Kenangan has proven regional scale and reached profitability, but limited disclosure and a reported secondary-sale range that already embeds a premium multiple keep the stock-picking answer at track rather than buy.

Valuation

$1.3B

Revenue run-rate

$200M

Growth

55%

Apeel Sciences

Apeel has a credible product, customer, and sustainability story, but the public file is still too thin on economics and financing quality to justify taking price at a premium valuation without more diligence.

Valuation

$2B

Revenue run-rate

$150M

Egnyte

Egnyte is a rare profitable, founder-led content platform with durable regulated-vertical niches, but its ~$1.5B PE-era valuation, opaque financials, and structural exposure to Microsoft/Google bundling warrant close monitoring rather than conviction.

Valuation

$1.5B

Revenue run-rate

$128M

ARR

$128M

Cadence

Cadence is a high-growth AI chronic care platform with strong clinical validation but material regulatory risk from RPM billing scrutiny that warrants close monitoring.

Valuation

$1.2B

Growth

200%

Freenome

Freenome's multi-omics cancer detection platform shows scientific promise but faces significant execution risk as a pre-revenue company with competitive pressure and pending clinical data disclosure.

Valuation

$1.1B

Sudo AI

Sudo AI is a credible frontier robotics company to track, but the current public evidence supports technical promise more strongly than commercial proof, making the reported ~US$1.9B valuation look stretched rather than clearly investable today.

Valuation

$1.9B

COOWA

COOWA is the most commercially mature urban-robotics company in this report cohort — real revenue, operating profitability, and 10,000+ deployed robots — but the US$3B valuation at ~21x revenue multiples prices near-flawless execution for an IPO that has not yet been filed.

Valuation

$3B

Revenue run-rate

$140M

D-Robotics

D-Robotics has assembled credible developer ecosystem depth, post-Horizon engineering pedigree, and $370M in capital to pursue an edge-AI-chip platform play in robotics — but the unicorn valuation asks investors to price a revenue story that public evidence has not yet confirmed.

Valuation

$1.5B

DayOne Data Centers

DayOne is a premium digital-infrastructure asset with genuine hyperscale demand and unusual capital access, but the reported US$20B valuation remains ahead of the public evidence on earnings power and contract quality.

Valuation

$20B

Rokid

Rokid is China's most proven independent AI/AR glasses maker, with 300,000+ units ordered in 2025 and genuine international traction — but the US$2.1B pre-IPO mark demands post-listing revenue and margin proof that has not yet been publicly disclosed.

Valuation

$2.1B

Solace

Solace has built a compelling, reimbursement-backed patient-advocacy platform with real national scale, but the public record still supports only a track stance because core economics, payer mix, and Series C terms remain too opaque for a clean late-stage underwrite.

Mesh

Mesh has credible product and partner proof in a large, fast-forming stablecoin-payments market, but the public record still lacks the revenue and margin evidence needed to underwrite its $1B valuation with conviction.

Valuation

$1B

LiveKit

LiveKit has real strategic relevance in voice AI infrastructure, but the current $1B mark merits tracking rather than aggressive underwriting until ARR, margins, retention, and concentration are disclosed.

Valuation

$1B

Kapital Bank

Kapital looks like a real full-stack SMB banking platform with regulated-bank profitability and scale, but public evidence still does not show the consolidated revenue, cap-table, and preference-stack detail needed to underwrite the September 2025 unicorn price aggressively.

Valuation

$1.3B

VoltaGrid

VoltaGrid has real hyperscale demand and sponsor validation, but the current valuation still requires faith in an unaudited 2028 EBITDA target, a smooth Propell manufacturing ramp, and favorable regulatory outcomes.

Valuation

$10B

Nearfield Instruments

Nearfield has real strategic and technical proof, but the current $1.6B round still lacks enough public financial disclosure to justify a buy recommendation.

Valuation

$1.6B

Nordic Knots

Nordic Knots looks like a genuinely strong premium home-textiles brand with real growth and profitability, but the public record still supports a research-more call because the March 2026 valuation implies a ~31x revenue multiple without audited financial disclosure.

Valuation

$2.2B

Revenue run-rate

$70M

Growth

85%

X Square Robot

X Square Robot is a strategically credible embodied-AI startup with a real model-and-data flywheel and elite capital backing, but opaque economics and a stretched valuation keep the right call at research-more.

Valuation

$2.8B

Linkerbot

Linkerbot shows unusually strong, multiply-corroborated shipment scale and top-tier investor backing for a dexterous-hand maker, but a near-total absence of audited financials, independent market-share verification, and reconciled funding-round data mean its $3B valuation cannot yet be independently underwritten.

Valuation

$3B

Global Eggs

Global Eggs is a scaled and strategically credible multinational egg consolidator, but the announced valuation already prices in integration success and earnings quality that the public file does not fully prove.

Valuation

$8B

Revenue run-rate

$2B

Zhijian Power / 至简动力 / Simplexity Robotics

Elite Li Auto pedigree and strong early sponsorship make Zhijian Power worth tracking, but public evidence still stops at PoC and unnamed cooperation, leaving the reported >US$1B valuation unsupported.

Advanced Digital Gaming Technology

ADGT is a well-capitalized, PE-and-strategic-partner-backed UAE gaming-payments platform with a credible regulatory positioning claim, but it has no public operating track record and its widely repeated ~US$1 billion valuation is not verified by any primary disclosure.

Rox

Rox shows real enterprise product signal, but the reported $1.2B price still looks stretched on public economics.

Valuation

$1.2B

Astromech

Astromech may be building a differentiated biological-AI platform with strong Colossal adjacency, but the public record still lacks the customer, revenue, and validation proof needed to underwrite the reported $2 billion valuation confidently.

Valuation

$2B

AIsphere

AIsphere has enough product, scale, and financing evidence to stay investable, but the current unicorn-level price is still too under-documented on ARR quality, margin durability, and security terms to justify a buy call.

Valuation

$1B

ARR

$40M

Advanced Machine Intelligence

AMI is an exceptionally capitalized physical-AI lab with elite leadership, but public evidence supports research-more rather than buy because product, customer, economics, and governance proof trail its seed valuation.

Valuation

$4.5B

JSW One MSME

JSW One has built a strategically relevant industrial-procurement and embedded-finance platform for Indian MSMEs, but incomplete disclosure on current terms, profitability, and credit quality makes it a continue-diligence case rather than an invest-now one.

Valuation

$1B

Growth

179.6%

Axiom

Axiom is one of the most credible proof-first AI startups in public evidence, but commercialization and valuation support remain under-disclosed.

Valuation

$1.6B

Starcloud

Starcloud has enough real technical proof to merit continued diligence, but the current public price looks expensive relative to the still-thin customer, reliability, regulatory, and economic disclosure base.

Valuation

$1.1B

Venice AI

Venice AI pairs rare profitability and strong adoption in a growing private-AI market with token and regulatory uncertainty, making it a high-quality but high-variance opportunity to monitor rather than commit to at ~14x ARR.

Valuation

$1B

Revenue run-rate

$70M

ARR

$70M

Joulent

A well-partnered, richly valued option on co-located power for AI data centers—strong contracted proof, but pre-revenue, single-customer, and capital-intensive.

Valuation

$5B

Recursive Intelligence

Elite AlphaChip founders and a real market bottleneck make Recursive Intelligence worth tracking, but a $4B entry price is ahead of public customer and revenue proof.

Valuation

$4B

Oxide

Oxide has built a differentiated rack-scale private-cloud platform, but the visible ~$1.6B Series C mark already prices in execution that public disclosures do not yet prove.

Valuation

$1.6B

Dash0

Dash0 shows credible product-market pull and exceptional founder-market fit, but the unicorn valuation is difficult to underwrite without public revenue-quality metrics.

Valuation

$1B

Mosyle

Mosyle appears to be a credible, scaled Apple-only management and security platform, but public evidence is still too incomplete and internally inconsistent to underwrite a confident buy case at or above a unicorn valuation.

Valuation

$899M

Cart.com

Cart.com has built a real scaled unified commerce and logistics platform with named enterprise customers and repeat institutional capital, but opaque revenue, debt, and preference economics make the $1.6B benchmark hard to underwrite for new investors.

Valuation

$1.6B

Firmus Technologies

Firmus has unusually strong strategic validation for a private AI-infrastructure platform, but the current valuation already assumes successful multi-campus commercialization before public economics are mature enough to underwrite aggressively.

Valuation

$1.2B

ModelBest

ModelBest looks like an investable edge-AI company with real open-source traction and strategic investor support, but the current unicorn-threshold price is still under-documented on revenue, pricing, and security terms.

Valuation

$1B

Neo Group

Neo has built a credible premium-wealth platform with meaningful asset scale and strong investor backing, but the public file still lacks the revenue, margin, governance, and retention disclosure needed to underwrite the March 2026 unicorn valuation with high conviction.

Valuation

$1.1B

Keyrock

Keyrock looks strategically relevant and increasingly regulated, but the March 2026 unicorn valuation still runs ahead of public underwriting evidence because current economics and round terms remain largely undisclosed.

Valuation

$1.1B

Brevo

Brevo appears to be a scaled and increasingly profitable European marketing SaaS platform, but the current unicorn-era pricing is harder to underwrite than the company-quality story because public disclosure is still thin.

Valuation

$1.2B

OYO

Track: OYO's filed turnaround and global-scale repositioning now support a real IPO conversation, but leverage, litigation, profit-quality adjustments, and a stretched $7-8 billion ask still require disciplined underwriting.

Valuation

$7.5B

Revenue run-rate

$732M

Growth

16%

Moloco

Moloco appears to be a scaled, profitable, strategically relevant adtech platform, but the lack of current audited financials, retention data, and clean post-2023 transaction evidence keeps the investment case in track territory rather than buy territory.

Valuation

$2B

Inceptio Technology

Inceptio has unusually strong commercialization proof for a private autonomous-trucking company, but the lack of public financial disclosure keeps the investment case in track rather than buy territory.

Tibber

Tibber has a real smart-energy product and household flexibility platform, but the public record is still too conflicted and incomplete to justify a high-confidence investment stance at the current private-market mark.

Valuation

$2.2B

Digital Asset

A category-leading institutional-blockchain platform with rare TradFi backing and live market-infrastructure workflows, but priced ahead of any disclosed revenue — a high-conviction, high-uncertainty track candidate.

Valuation

$2B

Mirendil

Mirendil pairs an elite ex-Anthropic/Google founding team and top-tier backing (a16z, Kleiner Perkins, NVIDIA) with a ~$1B seed valuation despite no product, no benchmarks, no revenue, and no customers. The talent-and-thesis case is real; the price is underwritten almost entirely on founder pedigree and TAM. Research-more / track at the current reported price; re-evaluate after the first technical proof points and design-partner evidence appear.

Valuation

$1B

AppsFlyer

AppsFlyer is a scaled, profitable, independent measurement leader whose June 2026 $2.7B strategic round validates the franchise, but a March 2026 SDK trust event, opaque financials, and platform dependency make it a disciplined track-to-conditional-buy rather than a clean entry.

Valuation

$2.7B

Revenue run-rate

$400M

Upscale AI

Strong AI-networking tailwinds and funding momentum justify a track rating, but insufficient public commercial proof keeps Upscale AI below a buy at $2B.

Valuation

$2B

AlphaSense

AlphaSense is a category-leading AI market-intelligence franchise with exceptional growth and a full but defensible $7.5B valuation, gated only by undisclosed profitability and retention.

Valuation

$7.5B

Revenue run-rate

$600M

ARR

$600M

Growth

20%

Beren Therapeutics

Beren has credible orphan-drug approval optionality and better financing than most single-asset biotechs, but approved competitors, structured-capital leakage, and still-limited public launch economics make the current private benchmark worth tracking rather than chasing.

Twenty

Twenty may be an early category leader in offensive cyber software, but the current public record supports only a strategic watch position rather than a high-conviction buy at $1B.

Valuation

$1B

Ollin Biosciences

Ollin combines unusually strong private financing and encouraging OLN324 head-to-head data, but opaque economics and undisclosed valuation keep the investability call at watchlist level rather than conviction underwriting.

Nimble Robotics

Nimble has credible product and strategic proof, but the $1B unicorn anchor still needs stronger public evidence on utilization, customer durability, and unit economics.

Valuation

$1B

Assort Health

Assort Health shows real product-market pull in healthcare patient access, but opaque unit economics and meaningful privacy, workflow-safety, and competitive risks keep the current $1.2B mark in watchlist territory rather than clear buy territory.

Valuation

$1.2B

GSR

GSR has credible scale, institutional positioning, and strategic-bank validation, but sparse current financial disclosure and under-defined financing terms keep the unicorn valuation in research-more territory.

Valuation

$1B

Parallel

Parallel has credible agent-web infrastructure, real workflow proof, and elite backers, but the $2 billion Series B asks investors to underwrite economics that remain largely private.

Valuation

$2B

Slash

Research more: Slash's growth and product differentiation look real, but the $1.4 billion Series C already assumes margin durability and control depth that public evidence still does not verify.

Valuation

$1.4B

Revenue run-rate

$250M

OpenRouter

OpenRouter has real strategic relevance in the multi-model AI stack, but the public evidence still does not support underwriting a reported $1.3B valuation with high conviction.

Valuation

$1.3B

Unico

Track: Unico has real scale, product breadth, and recent profitability momentum in a structurally growing Brazil identity market, but the active Serasa Experian litigation, thin public disclosure, and stale 2022 valuation mark keep the current risk-reward from clearing a buy threshold.

Valuation

$2.6B

Growth

34%

ShareChat

Track: ShareChat still owns meaningful vernacular-social and short-video scale in India and has repaired operations faster than many consumer-internet peers, but the stale $5 billion mark remains stretched until cleaner financing terms, audited cash-flow proof, and steadier leadership support a firmer IPO case.

Valuation

$5B

GetYourGuide

GetYourGuide appears to be a scaled category leader in travel experiences with credible profitability momentum, but private-financial opacity and marketplace-quality risks keep the investment stance at track pending audited evidence.

Valuation

$1.9B

Revenue run-rate

$1.2B

Exiger

Exiger has credible scale, strong federal-grade differentiation, and a plausible AI-led supply-chain workflow moat, but opaque financial disclosure and concentration risks keep the reported unicorn valuation from being fully underwritten.

Valuation

$1.2B

Rogo

Rogo is a fast-compounding, well-financed vertical AI platform for Wall Street with concrete institutional traction, but its $2 billion Series D price has outrun every public revenue, margin, and retention disclosure, warranting research-more rather than a directional buy or avoid call.

Valuation

$2B

Omni

Strong founder-market fit and a coherent governed-semantic platform have produced real enterprise traction, but thin public durability disclosure and rising bundle pressure leave Omni as a track, not buy, at $1.5B.

Valuation

$1.5B

Tide

Tide has built a scaled UK-and-India SME finance platform with improving filed financials, but the latest $1.5B valuation already assumes better monetisation, cleaner support outcomes, and clearer group economics than public evidence currently proves.

Valuation

$1.5B

Growth

56%

StepFun

StepFun pairs genuine device-and-automotive distribution and a record 2026 financing sprint with a $10-12 billion IPO target that public disclosure -- thin, unaudited, and third-party-reported -- cannot yet underwrite.

Valuation

$11B

Black Forest Labs

Black Forest Labs has real technical and commercial momentum in visual AI, but the current private mark still requires deeper diligence on economics, concentration, and regulatory durability.

Valuation

$3.3B

Revenue run-rate

$96.3M

Granola

Granola's bot-free meeting-notes product shows strong, well-corroborated funding momentum and customer proof, but its $1.5B Series C valuation cannot be checked against any disclosed revenue, ARR, or margin figure.

Valuation

$1.5B

Wonderful

Wonderful may become a category-defining enterprise AI workflow platform, but the public evidence does not yet justify price-insensitive conviction at a $2B valuation. Product depth and customer proof are real; retention, margin, concentration, and preference-stack evidence are not.

Valuation

$2B

Bose Quantum

Bose Quantum looks strategically important and technically credible enough to keep diligencing, but public disclosure is too thin on revenue, round terms and valuation to justify underwriting at an undisclosed price.

Andromeda

Andromeda appears to solve a real GPU procurement problem and has meaningful early traction, but the current $1.5B price is hard to underwrite without better evidence on margin quality, concentration, and governance.

Valuation

$1.5B

Revenue run-rate

$100M

Nexthop AI

Nexthop has a credible open-Ethernet AI-networking product and strong investor backing, but thin public proof on revenue, customer breadth, and margins keeps the company in track-not-buy territory at the current $4.2 billion mark.

Valuation

$4.2B

Profound

Profound is the best-funded and most-recognized platform in a real and rapidly growing category, but the $1B valuation looks stretched without ARR disclosure, and incumbent SEO vendors are closing the product gap quickly.

Valuation

$1B

PaleBlueDot AI

PaleBlueDot AI shows credible demand and differentiated APAC-oriented AI compute positioning, but the >$1B Series B price is hard to underwrite without disclosed ARR, margins, or customer breadth.

Valuation

$1B

Flapping Airplanes

Flapping Airplanes is an elite-talent, high-conviction AI research bet worth monitoring, but the public record does not support underwriting a $1.5 billion entry price while the company still has no product, no revenue, and no published benchmark evidence.

Valuation

$1.5B

TensorWave

TensorWave has real infrastructure and customer proof, but the June 2026 $1.55 billion mark still looks stretched until debt structure, customer quality, and audited operating metrics become clearer.

Valuation

$1.6B

Generalist AI

Track — Generalist AI pairs elite embodied-AI talent and a potentially differentiated data engine with a relatively lower peer valuation, but public evidence still stops short of revenue, named customers, and deployment-grade validation.

Valuation

$2B

DeepWay

DeepWay has built uncommon autonomous-trucking commercial scale in China, but the current investment case is still dominated by thin truck-hardware margins, single-source dependencies, and an unproven transition to high-margin autonomy software.

Revenue run-rate

$582M

Growth

101.2%

Redaptive Inc.

Redaptive looks strategically credible and financing-capable, but current public evidence still does not support a confident entry price above the last visible unicorn-era mark.

Valuation

$1B

Xingyun Group (行云集团)

Xingyun Group has real cross-border infrastructure, brand relationships, and optionality through Polibeli, but opaque parent financials, active governance/regulatory disputes, and a stretched implied valuation keep the investment view at research-more rather than buy.

Valuation

$2.2B

Revenue run-rate

$42.3M

Astribot

Astribot is China's leading cable-driven humanoid-robot startup, reaching unicorn status on differentiated actuation technology and unusually fast commercial traction, but undisclosed financials and unproven autonomy keep this a qualified, medium-confidence Buy rather than a clean underwrite.

Valuation

$1.4B

AscenPower

AscenPower has real policy-backed momentum, a credible automotive-grade SiC manufacturing buildout, and a publicly recognized unicorn narrative, but revenue opacity, customer-proof gaps, and heavy capex execution risk keep the company in RESEARCH-MORE territory rather than a high-conviction buy.

SVOLT Energy Technology

SVOLT has enough real manufacturing scale, export momentum, and technology ambition to merit continued diligence, but the current headline valuation looks stretched versus stale financial transparency, unresolved concentration risk, and heavy capital intensity.

Valuation

$7.2B

Chando

Chando has real beauty-market scale, strategic outside backing, and a live HK IPO path, but the current evidence still supports only a track stance because brand concentration, family control, and marketing-heavy economics keep the valuation fair near the last round rather than clearly attractive.

Valuation

$1B

Revenue run-rate

$745M

Growth

15.6%

Slate Auto

Slate is pursuing a credible white-space thesis in affordable electric trucks, but public evidence still supports only a track stance because launch execution, preorder conversion, service readiness, and valuation precision remain unresolved ahead of late-2026 deliveries.

Firestorm Labs

Firestorm combines a differentiated deployable microfactory thesis with credible U.S. military traction, but public underwriting is constrained by opaque financials, concentrated government demand, and no verified post-money valuation.

BlueVoyant

BlueVoyant is a credible late-stage cybersecurity platform with real MDR and TPRM scale, differentiated regulated-industry positioning, and strong Microsoft ecosystem leverage, but its private-company opacity and unresolved valuation/revenue conflicts justify a track posture rather than a conviction buy.

Valuation

$1B

Revenue run-rate

$214M

ARR

$214M

AI² Robotics

AI² Robotics is a credible Chinese embodied-AI contender with real strategic backing and an unusually large early customer contract, but the February 2026 unicorn valuation still runs ahead of disclosed fundamentals and keeps the company in research-more territory.

Valuation

$1.4B

Ro

Ro has built a real scaled asset in D2C healthcare with strong GLP-1 growth and meaningful vertical integration, but the stale $7B mark, lack of audited disclosure, and heavy dependence on regulated manufacturer channels keep the company in watchlist rather than clear-buy territory.

Valuation

$7B

Revenue run-rate

$598M

Growth

66%

Outrider

Outrider looks like one of the most credible autonomous yard-operations specialists in market, but the absence of public valuation, revenue, pricing, and concentration data keeps the investment case below underwriting grade for now.

Factorial Energy

Factorial has unusually strong OEM validation for a solid-state battery startup, but the stock already prices in strategic option value despite zero revenue, finite runway, dilution overhang, and unresolved manufacturing-scale risk.

Valuation

$1.2B

SecurityScorecard

SecurityScorecard is a category-defining cyber risk ratings platform with real enterprise scale and strong strategic positioning, but a five-year-stale $1B valuation, secondary market compression to $360–$470M, and undisclosed NRR and gross margin make this a track recommendation pending economic validation.

Valuation

$1B

Revenue run-rate

$150M

ARR

$150M

Pine Labs

Track: Pine Labs is a scaled Indian merchant-commerce platform with improving profitability and credible valuation upside, but tax, breakage, and disclosure risks still block a cleaner buy case.

Valuation

$2.2B

Revenue run-rate

$308M

Growth

19%

GoCardless

GoCardless has built a strong European bank-payments position and is showing credible profitability improvement, but the pending Mollie sale, price opacity, and unresolved regulatory/governance details keep the investment case at Track rather than Buy.

Growth

22%

eMed

eMed has a credible employer GLP-1 distribution story and marquee strategic backing, but the $2B+ valuation appears stretched relative to public digital-health comps because revenue, customer concentration, and unit economics remain materially undisclosed.

Valuation

$2B

CAIT

CAIT is a strategically credible CATL platform extension with real OEM interest and a strong parent moat, but today’s public evidence supports tracking rather than underwriting the business aggressively because revenue, customer conversion, and standalone economics remain opaque.

Valuation

$1.4B

Science Corporation

Science Corporation has the strongest clinical evidence ever published for implantable vision restoration, but the $1.5B entry mark outpaces expected value until CE Mark outcome and EU commercial traction are confirmed.

Valuation

$1.5B

9fin

9fin has built a credible AI-native platform with proven penetration across all top-10 global investment banks and 350+ institutions, warranting a Track stance while financial opacity prevents a clean underwrite of the $1.3 billion valuation.

Valuation

$1.3B

Signifyd

Signifyd is a real enterprise commerce-protection platform with differentiated guarantee-backed products and credible customer proof, but the absence of current valuation, margin, and reserve disclosures makes the company more suitable for monitoring than underwriting at the last public unicorn mark.

Valuation

$1.3B

Revenue run-rate

$292.8M

Highway

Highway has credible category leadership and customer adoption in freight fraud prevention, but public disclosure is still too thin for a price-sensitive investment call.

Merama

Merama looks stronger than many global aggregator failures, but thin public disclosure, debt-funded expansion, and brand/platform concentration keep the recommendation at TRACK with medium confidence and a stretched valuation stance.

Mammoth Biosciences

Mammoth has elite science and partner validation but remains preclinical and under-disclosed.

Valuation

$1B

Rentberry

Rentberry looks like a real rental-workflow product with global reach and persistent financing access, but public evidence still supports only a cautious, further-diligence stance because valuation, governance, and monetization disclosures remain materially inconsistent.

Valuation

$138.7M

Endless

Endless looks like a credible but still opaque early-stage Web3 infrastructure bet: the financing signal is real, but the public file is too thin on revenue, users, governance, and treasury quality to justify blind underwriting at the current $1B mark.

Valuation

$1B

Cosm

Cosm has enough strategic traction to stay on the watchlist, but the company is not yet publicly underwritable at a clean price because venue economics and Series C terms remain opaque.

Valuation

$1B

Infinite Reality

Infinite Reality has assembled real immersive-commerce and media assets, but the gap between its confirmed fundamentals and its self-reported valuation remains so extreme that the equity case is currently dominated by governance, legal, and financing downside rather than platform upside.

Valuation

$5.1B

Reflection AI

Reflection AI combines elite founder quality, investor support, and sovereign-AI optionality, but the public record still lacks a shipped frontier model, named commercial customers, and revenue proof to underwrite the discussed 2026 valuation.

Valuation

$8B

RapidSOS

RapidSOS has credible category leadership in emergency-response intelligence and interoperability, but the public file is still too thin on revenue quality and margin structure to support a buy decision at or above the latest private marker.

Valuation

$1B

Raise Financial Services

Raise/Dhan looks like a real, profitable challenger in Indian retail broking, but concentration in derivatives and thin private-company disclosure keep the last-round valuation in the fair rather than clearly attractive bucket.

Valuation

$1.2B

Fundamental Technologies

Fundamental Technologies carries genuine technical differentiation and elite distribution, but its $1.4 billion valuation prices success ahead of any disclosed revenue or retention data — the right posture is track and re-evaluate at first ARR disclosure.

Valuation

$1.4B

Etraveli Group

Etraveli is a scaled, EBITDA-positive hybrid flight-commerce platform with real partner validation, but the undisclosed current entry price, leverage opacity, and partner-concentration economics keep the asset in research-more territory on public evidence alone.

Juniper Square

Juniper Square looks like a credible category leader in private-markets fund operations, but the public-evidence case is stronger for tracking than aggressive buying because valuation is full and audited financial disclosure remains limited.

Valuation

$1.1B

Revenue run-rate

$139.8M

ARR

$139.8M

Growth

29%

Infobip

Scaled private CPaaS leader with improving profitability and credible infrastructure moat, but valuation conviction is capped by disclosure and capital-structure opacity.

Valuation

$3B

Revenue run-rate

$2.3B

Growth

17%

Sun King

Sun King is a category-leading PAYG solar platform with unmatched distribution and capital-markets innovation, but opaque financial disclosure and frontier-market credit/FX risk justify disciplined valuation underwriting rather than an immediate buy.

Valuation

$1.4B

SmartHR, Inc.

SmartHR combines a strong domestic compliance-software position with real ARR scale, but investors still need private-company economic evidence before paying a premium growth valuation.

Valuation

$1.6B

Revenue run-rate

$100M

ARR

$100M

Growth

45%

Tekion Corp

Tekion is the leading cloud-native DMS disruptor in a $6.8B market, with exceptional growth velocity and a defensible technical moat, but pre-profitability status and CDK competitive response create meaningful risks.

Valuation

$4B

ARR

$280M

Growth

97%

NRR

112%

Motive

Motive's AI fleet platform has real scale and strong customer proof, but IPO execution and an active Samsara trade-secret suit are the key overhang risks at $3.08B.

Valuation

$2.9B

Revenue run-rate

$500M

ARR

$500M

Growth

117%

NRR

126%

Crusoe Energy Systems

Crusoe has built a differentiated power-first AI infrastructure platform, but the post-Series-E valuation already assumes successful hyperscale execution that public evidence does not yet fully underwrite.

Valuation

$10B

Viam

Viam offers a credible and differentiated machine-software control plane backed by strong founder-market fit and growing enterprise proof points, but undisclosed revenue and valuation make it a track rather than buy at this stage.

Tianji

Tianji appears to be a real and scaling Chinese robotics supplier with credible dual-arm productization, legacy industrial deployments, and top-tier strategic funding, but the May 2026 RMB8-10 billion valuation still outruns the public financial evidence needed to underwrite it confidently.

Valuation

$1.3B

SHEIN

SHEIN combines one of the most powerful demand-sensing and supply-chain engines in global consumer internet with one of the heaviest regulatory, legal, and reputational overhangs in retail; the business is too large and capable to dismiss, but the current risk stack and uncertain IPO path support TRACK rather than an aggressive buy posture.

Valuation

$45B

Revenue run-rate

$38B

Growth

19%

Tessera Therapeutics

Tessera has achieved the pivotal transition from platform company to clinical-stage asset, with TSRA-196 entering a global Phase 1/2 trial in early 2026 under FDA Fast Track and Orphan Drug designations. The Regeneron collaboration ($150M + $125M milestones) provides non-dilutive validation and a credible path to commercialization. Gene Writing's large-payload, no-double-strand-break mechanism is technically differentiated from CRISPR but unproven in humans. The January 2026 workforce reduction signals financial discipline but also execution risk concentration. The 2022 $1.7B valuation may not fully reflect current biotech market conditions; investors should model a 2028–2030 data readout horizon. A Track / research-more position is warranted pending Phase 1 safety and efficacy data.

Valuation

$1.7B

Synchron

Synchron has achieved the critical clinical derisking milestone of a feasibility trial primary endpoint and is now the only endovascular BCI with a clear path to FDA PMA. Its minimally invasive profile eliminates the craniotomy barrier — the primary adoption constraint for brain implants — and its Apple and NVIDIA integrations validate the platform for commercial deployment. The $200M Series D at an implied $1B+ valuation prices in successful pivotal trial execution; failure to meet the pivotal endpoint or obtain CMS reimbursement would be existential. A high-conviction track position for investors with multi-year medical device timelines.

Valuation

$1B

Blitzy

Blitzy has proven, named enterprise product-market fit with measurable velocity gains, but faces intense competition at a stretched $1.4B valuation that prices in undisclosed ARR growth.

Valuation

$1.4B

nesto

nesto's C$1.47 billion Series E valuation is anchored by genuine operational scale — C$80B+ MUA, C$37B+ 2026 originations, and confirmed profitability — and by high-quality institutional backing from La Caisse and Fidelity, but revenue opacity, balance-sheet funding dependency, and unresolved M3 channel concentration prevent conviction; the evidence supports a track recommendation at a fair valuation.

Valuation

$1.1B

Musinsa

Musinsa combines category leadership, real profitability, and strong Korean fashion consumer mindshare, but the current private/IPO valuation ambition runs materially ahead of disclosed fundamentals and the company still carries regulatory, trust, and international-execution risk.

Valuation

$3.1B

Revenue run-rate

$1B

Growth

18.1%

KreditBee

KreditBee has credible scale, profitability, and a fresh unicorn valuation, but the public evidence does not yet make the April 2026 price look clearly cheap versus its credit, funding, and disclosure risks.

Valuation

$1.5B

Corgi Insurance

Corgi is a high-conviction Series B1 insurtech with extraordinary revenue traction and a compelling full-stack carrier model, but a stretched $2.6B valuation, limited claims history, and unaudited financials warrant disciplined diligence before further investment.

Valuation

$2.6B

ARR

$40M

Eve

Eve has real plaintiff-law workflow traction and elite investor backing, but public revenue and retention opacity still make the unicorn valuation difficult to underwrite aggressively.

Valuation

$1.1B

Tractian

Credible industrial AI platform with strong customer proof and integrated product design, but incomplete financial disclosure keeps the investment case short of full underwriting.

Valuation

$723M

Mews

Mews is the strongest independent challenger to Oracle's hotel PMS hegemony, with genuine category leadership in cloud-native hospitality infrastructure, a $2.5B Series D, and compelling 55% SaaS gross-profit growth — but financial opacity prevents full valuation underwriting and an NYU 2026 study signals structural headwinds for all-in-one platforms.

Valuation

$2.5B

Altruist

Altruist has built a defensible vertically integrated RIA custody platform with strong growth metrics, but proceed-with-diligence is warranted pending audited financials and cap-table transparency.

Valuation

$1.9B

Just Salad

Just Salad looks like a real scaled concept with differentiated sustainability branding and credible growth momentum, but the current $1 billion mark already prices in strong execution while audited economics, capital-structure details, and retention data remain private.

Valuation

$1B

Revenue run-rate

$195M

Growth

21.9%

SPAN

SPAN has credible product differentiation and increasingly important channel partners, but the public evidence still supports TRACK rather than a high-conviction buy because valuation markers and operating disclosure remain too far apart.

Valuation

$1B

Defense Unicorns

Defense Unicorns has real attributable traction in air-gapped defense software delivery, but the $1B+ Series B valuation still depends on economics the public record does not disclose.

Valuation

$1B

Neysa

Neysa has a credible sovereign-AI infrastructure wedge and sponsor-backed scale capital, but the current ~$1.4B price is not yet supported by public evidence on revenue quality, utilization, margins, or debt structure.

Valuation

$1.4B

Mytra

A differentiated full-pallet warehouse-automation platform with real customer proof and top-tier backers, but limited public financial disclosure, unresolved concentration questions, and a possibly stretched private valuation keep Mytra in research-more territory rather than clear underwriting range.

Valuation

$2B

Tuduoduo

Tuduoduo is a scaled and profitable industrial B2B platform with credible category depth, but unresolved parent-governance, compliance, and disclosure gaps keep the supportable call at research-more rather than buy.

Valuation

$2.2B

Revenue run-rate

$4.1B

Growth

15.6%

Avatr Technology

Avatr is a strategically backed premium EV platform with credible scale and improving disclosed margins, but weak 2026 momentum, partner dependence, and limited valuation transparency keep the supportable call at research-more.

Valuation

$4.4B

Growth

98.5%

CATL Intelligent Technology

CATL Intelligent has a credible parent-backed chassis-platform story and real AVATR-linked technical proof, but thin standalone disclosure, high customer concentration, and policy sensitivity still justify a research-more stance rather than a pricing-confident underwriting call.

Valuation

$1.4B

GalaxySpace (银河航天)

GalaxySpace is one of China's most credible private LEO broadband and satellite-manufacturing platforms, but public disclosure still falls well short of what is needed to underwrite a $4.4B valuation with confidence.

Valuation

$4.4B

LMArena

LMArena appears to be the category leader in AI evaluation, but the $1.7B Series A price leaves little margin of safety until governance, neutrality, and customer-concentration questions are resolved.

Valuation

$1.7B

Revenue run-rate

$30M

Kriya Therapeutics

Kriya has assembled a rare combination of capital, manufacturing ambition, and chronic-disease gene-therapy scope, but the public evidence base is still too thin on clinical efficacy, valuation, and burn discipline to support a clear buy posture.

Inari Agriculture

Inari has raised enough capital and assembled enough crop-specific technical proof to warrant continued diligence, but the lack of public commercialization economics, ongoing IP litigation, and the 2026 workforce reset keep the investment case in research-more territory rather than buy territory.

Valuation

$2.2B

Shihang Intelligent

Shihang Intelligent shows unusually strong financing, order, and field-validation signals for a 2023-founded marine-robotics company, but opaque valuation, revenue conversion, and regulatory execution keep it in research-more territory.

Impulse Space

Impulse Space has unusually strong public proof for a private orbital-logistics startup—three flown Mira missions, credible commercial and government backlog, and founder-market fit—but opaque revenue, burn, and preference terms plus Helios execution risk make research-more the disciplined call.

Valuation

$4.3B

GigaAI

GigaAI is a technically ambitious Beijing physical-AGI company with strong 2026 capital access and credible early deployment signals, but public evidence still does not support underwriting its unicorn valuation with the same confidence one would apply to a more disclosed robotics peer.

Valuation

$1.5B

Focused Energy

Focused Energy has emerged as Europe's strongest laser-fusion financing story, but absent valuation disclosure, customer contracts, or integrated high-repetition technical proof, the investable stance remains research-more pending Biblis execution, financing-roadmap clarity, and subsystem-to-system validation.

Revenue run-rate

$0M

Flourish Inc.

Flourish combines rare founder pedigree with a differentiated energy-efficiency thesis, but public evidence is still far too thin to underwrite a $2.5B pre-product valuation with conviction.

Valuation

$2.5B

Ent

Ent is a high-pedigree, high-ambition workspace security startup with a rare $100M seed and credible product wedge, but the absence of disclosed financials, named customer depth and independent efficacy benchmarks makes it a monitor-now rather than invest-now situation.

Seekr Technologies

Seekr pairs genuine defense/intelligence AI traction and a credible trustworthy-AI platform with an extreme ~67x revenue entry multiple and opaque economics, supporting only a research-more stance until audited financials and financing terms are disclosed.

Valuation

$1.2B

Revenue run-rate

$18M

DevRev

DevRev is a structurally differentiated AI-native enterprise platform with founder pedigree, rapid ARR growth, and a unique knowledge graph moat — but at 11.5x ARR it is priced for execution the company has not yet proven at scale.

Valuation

$1.2B

Revenue run-rate

$100M

ARR

$100M

Growth

43%

Narwal Robotics

Innovation-led premium robot vacuum-mop challenger with strong product reviews, fast revenue growth and a ~$1.4B unicorn tag, but a richly priced, opaque, China-manufactured hardware exporter exposed to tariff, commoditization and key-person risk.

Valuation

$1.4B

Revenue run-rate

$200M

Growth

130%

Agrovision

Category-defining premium berry platform with branded pricing power and meteoric growth, but a private, capital-intensive grower whose $1B+ mark and IPO ambitions rest on undisclosed financials and climate/tariff-exposed agriculture.

Valuation

$1B

Revenue run-rate

$400M

Geek+

Category-leading warehouse-robotics franchise with its first adjusted profit and #1 global AMR share, but priced for perfection as a China-headquartered hardware exporter exposed to tariff, margin and de-rating risk.

Valuation

$2.1B

Revenue run-rate

$442M

Growth

31.6%

Trellix

Trellix remains a scaled, relevant XDR platform with real enterprise and government reach, but declining revenues, a distressed capital structure, and unresolved breach-related trust risk make it a diligence-heavy situation rather than a clean equity investment.

Revenue run-rate

$1.1B

Skeleton Technologies

Skeleton has credible traction in AI-power and grid-stability infrastructure, but manufacturing and disclosure gaps make a pre-IPO entry hard to price with conviction.

Trackunit

Trackunit has genuine category leadership in construction telematics and strong recurring-revenue quality, but the 2025 buyout price already bakes in much of that upside while leverage, macro sensitivity, and limited disclosure constrain conviction.

Valuation

$1.5B

Revenue run-rate

$186.5M

ARR

$119.5M

Growth

10%

PowerSchool

PowerSchool remains a category leader in K-12 vertical SaaS, but post-LBO opacity, unresolved breach liability, and a rich 7.8x ARR entry multiple leave the stock-less private asset in research-more territory rather than an investable buy.

Valuation

$5.6B

Revenue run-rate

$741M

ARR

$720.3M

Growth

18%

NRR

107%

Noah Medical

Noah Medical has built a credible robotic bronchoscopy platform with leading clinical evidence and real commercial traction, but the absence of any financial disclosure, two open FDA recalls, and an unconfirmed $2.0B valuation demand data-room validation before underwriting.

Valuation

$2B

Liquid Death